Woodline Partners LP Has $34.52 Million Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Woodline Partners LP boosted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 2.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,139,593 shares of the company's stock after purchasing an additional 90,940 shares during the quarter. Woodline Partners LP owned approximately 7.75% of Zevra Therapeutics worth $34,524,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics during the fourth quarter worth approximately $53,000. China Universal Asset Management Co. Ltd. bought a new stake in Zevra Therapeutics in the fourth quarter valued at about $94,000. Squarepoint Ops LLC raised its stake in Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after buying an additional 4,384 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of Zevra Therapeutics during the 4th quarter valued at approximately $145,000. Finally, Invesco Ltd. lifted its stake in Zevra Therapeutics by 19.6% during the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock worth $153,000 after purchasing an additional 3,007 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director John B. Bode acquired 10,000 shares of the business's stock in a transaction dated Wednesday, March 19th. The stock was acquired at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at $318,400. This represents a 33.33% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 2.40% of the stock is currently owned by corporate insiders.

Zevra Therapeutics Stock Performance

Shares of ZVRA traded up $0.08 during trading hours on Monday, reaching $8.65. 375,522 shares of the company's stock traded hands, compared to its average volume of 645,341. The firm has a market capitalization of $472.98 million, a price-to-earnings ratio of -4.39 and a beta of 1.87. The business's fifty day simple moving average is $7.59 and its two-hundred day simple moving average is $8.08. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The company had revenue of $20.40 million during the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the prior year, the business posted ($0.40) EPS. Analysts predict that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ZVRA. Canaccord Genuity Group raised their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday. Finally, JMP Securities set a $18.00 price target on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Zevra Therapeutics has an average rating of "Buy" and an average price target of $22.29.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.